Compare · CNMD vs ZYXI
CNMD vs ZYXI
Side-by-side comparison of CONMED Corporation (CNMD) and Zynex Inc. (ZYXI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and ZYXI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- CNMD is the larger of the two at $1.16B, about 3.9x ZYXI ($296.3M).
- Over the past year, CNMD is down 24.5% and ZYXI is down 94.1% - CNMD leads by 69.6 points.
- CNMD has hit the wire 2 times in the past 4 weeks while ZYXI has been quiet.
- CNMD has more recent analyst coverage (14 ratings vs 10 for ZYXI).
- Company
- CONMED Corporation
- Zynex Inc.
- Price
- $38.41+2.52%
- $0.13-31.48%
- Market cap
- $1.16B
- $296.3M
- 1M return
- +3.74%
- -77.93%
- 1Y return
- -24.48%
- -94.10%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- News (4w)
- 2
- 0
- Recent ratings
- 14
- 10
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Zynex Inc.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Latest CNMD
- SEC Form DEFA14A filed by CONMED Corporation
- SEC Form DEF 14A filed by CONMED Corporation
- SEC Form 4 filed by Beyer Pat
- CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by CONMED Corporation
- Amendment: SEC Form 4 filed by Lalomia Brent
- Amendment: SEC Form 4 filed by Schabacker Matthew
- Amendment: SEC Form 4 filed by Foust Hollie K
- Amendment: SEC Form 4 filed by Ferrell John D.
- Amendment: SEC Form 4 filed by Shagory Peter K
Latest ZYXI
- Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Zynex Financial Restructuring Puts Company on Path to Long-Term Success
- SEC Form 3 filed by new insider Aronzon Paul
- SEC Form 10-Q filed by Zynex Inc.
- Zynex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zynex Reports Third Quarter 2025 Financial Results
- Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee
- Zynex Sets Third Quarter 2025 Earnings Call
- SEC Form NT 10-Q filed by Zynex Inc.